No Data
No Data
Rakuria Pharma, Silicon Studio and others.
<3185> Yumetobou 11th subscription rights (with exercise price adjustment clause) issuance (3.6 million potential shares, raising approximately 55.7 billion yen). <3907> Silicon Studio share buyback, with a limit of 100,3900 shares (3.61% of issued shares), purchased on ToSTNeT-3 on the 18th. <4579> Lakolia's U.S. patent assessment of Nav1.7 and Nav1.8 sodium channel blockers (polycyclic ring inducers). <4597> Solegia's product development SP-05 (a...
DREAM VISION: Confirmatory letter.
DREAM VISION: Financial Report - Term 27 (2023/04/01 - 2024/03/31)
RIZAP-G Research Memo (7): The chocoZAP business has become profitable and will achieve profitability in the second half of the FY2024.
Business trend: 1. In the fiscal year ending March 2024, RIZAP Group's sales revenue was 16,629.8 million yen (an increase of 7.6% compared to the previous year), operating loss was 594 million yen (compared to a loss of 4,948 million yen in the same period last year), pre-tax loss was 4,524 million yen (compared to a loss of 7,031 million yen in the same period last year), and net loss attributable to the parent company's owner was 4,300 million yen (compared to a loss of 12,673 million yen in the same period last year) due to the black-figure conversion of the chocoZAP business.
DREAM VISION: Notice regarding the recording of subsidiary companies' stock valuation losses (extraordinary losses) in our individual accounts (Japanese standards) and differences from the previous fiscal year's actual values for individual...
DREAM VISION: Summary of financial results for the fiscal year ending 2024/3 [IFRS] (consolidated)
No Data